ProfileGDS5678 / 1430775_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 68% 64% 64% 64% 63% 68% 67% 65% 63% 64% 64% 63% 66% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.181568
GSM967853U87-EV human glioblastoma xenograft - Control 23.8072764
GSM967854U87-EV human glioblastoma xenograft - Control 33.8269964
GSM967855U87-EV human glioblastoma xenograft - Control 43.7905264
GSM967856U87-EV human glioblastoma xenograft - Control 53.7386563
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1672968
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0822867
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.875265
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7484363
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8459664
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.854664
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7263563
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0045466
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8336164